Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Fall on the Road
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Services
2023 Readersâ Choice Winners
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Orchard Therapeutics Plc ADR
(NQ:
ORTX
)
16.70
UNCHANGED
Last Price
Updated: 4:00 PM EST, Jan 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
16.70
Bid (Size)
16.52 (1)
Ask (Size)
17.13 (1)
Prev. Close
16.70
Today's Range
16.70 - 16.70
52wk Range
4.240 - 16.70
Shares Outstanding
184,260,149
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.
March 18, 2024
One-time treatment with Lenmeldy has shown the potential to restore enzymatic function to stop or slow disease progression, with up to 12 years of follow-up (median 6.76 years)
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
February 05, 2024
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Performance
YTD
+1.71%
+1.71%
1 Month
N/A
N/A
3 Month
+1.64%
+1.64%
6 Month
+178.33%
+178.33%
1 Year
+244.33%
+244.33%
More News
Read More
Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium
February 02, 2024
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics: Q3 Earnings Insights
November 13, 2023
Via
Benzinga
Why Orchard Therapeutics Stock Is Soaring Today
October 05, 2023
Via
The Motley Fool
Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy
January 25, 2024
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases
January 24, 2024
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD
December 11, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH
November 30, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX
November 28, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments
November 13, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023
October 26, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023
October 24, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Sarepta Therapeutics Stock Showing Rising Relative Strength
October 09, 2023
Via
Investor's Business Daily
ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX
October 06, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Crude Oil Down 2%; ConAgra Brands Earnings Top Views
October 05, 2023
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
October 05, 2023
Via
Benzinga
Why Accolade Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
October 05, 2023
Via
Benzinga
Dow Tumbles Over 100 Points; Constellation Brands Raises Profit Forecast
October 05, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Highly Rated Biotech Orchard Therapeutics Scores A Takeover, Shares Nearly Double
October 05, 2023
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023
October 05, 2023
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: SP® Plus Corporation (Nasdaq - SP), Orchard Therapeutics plc (Nasdaq - ORTX), Summit Materials (NYSE - SUM)
October 05, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Lamb Weston, SP Plus And Other Big Stocks Moving Higher On Thursday
October 05, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Dow Falls 50 Points; Weekly Jobless Claims Edge Higher
October 05, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Orchard Therapeutics PLC (NASDAQ: ORTX) Sets New 52-Week High in Thursday Session
October 05, 2023
Via
Investor Brand Network
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.